Rate My Professor Janine Haslett

Haslett has co-authored numerous peer-reviewed publications advancing knowledge in rheumatologic conditions. Key works include 'Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomised Clinical Trial of Colchicine for Gout Flare Prophylaxis' (2025, Arthritis Care & Research), 'The Influence of Patient Factors on the Population Pharmacokinetics of Colchicine: Implications for Safe and Effective Dosing' (2025, Clinical Pharmacokinetics), 'Incidence, Prevalence and Mortality of Rheumatoid Arthritis in Canterbury, Aotearoa New Zealand' (2025, Internal Medicine Journal), 'Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy' (2024, Arthritis Care & Research), 'Rheumatoid Interstitial Lung Disease in Canterbury, Aotearoa New Zealand – a Retrospective Cohort Study' (2024, Seminars in Arthritis and Rheumatism), 'Is Colchicine Prophylaxis Required with Start-Low Go-Slow Allopurinol Dose Escalation in Gout? A Non-Inferiority Randomised Double-Blind Placebo-Controlled Trial' (2023, Annals of the Rheumatic Diseases), 'The Development and Evaluation of Dose-Prediction Tools for Allopurinol in People with Gout' (2024, British Journal of Clinical Pharmacology), and 'The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease' (2023, Annals of the Rheumatic Diseases). Her publications have garnered approximately 290 citations, influencing clinical practices for urate-lowering therapies and flare prevention. Haslett's involvement underscores her role in translational research bridging clinical care and pharmacological advancements in gout and related disorders.